📰 Planegg News
Page 30 - Planegg News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Planegg. Real-time updates on events, politics, business and more.
March 15, 2023
EQS-News: MorphoSys AG / Key word(s): Annual Report MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Prov...
March 15, 2023
Topline data from the Phase 3 MANIFEST-2 study expected in early 2024 Monjuvi U.S. net product sales of US$ 25.3 million (€ 24.7 million) for the fourth quarter of 2022 and US$ 89.4 million (€ 84.9
March 14, 2023
EQS-News: MorphoSys AG / Key word(s): MiscellaneousLucinda Crabtree to Join MorphoSys as Chief Financial Officer 14.03.2023 / 21:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, March 14, 2023 Lucinda Crabtree to Join MorphoSys as Chief Finan...
March 2, 2023
Investegate announcements from MorphoSys AG, Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
March 2, 2023
MARTINSRIED (dpa-AFX) - German biopharmaceutical company MorphoSys AG (MOR) Thursday said it will stop work and operations on its pre-clinical research programs to optimize its cost structure.
March 2, 2023
MUNICH, GERMANY / ACCESSWIRE / March 2, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the company will stop work and operations on its pre-clinical research programs to optimize its cost
March 2, 2023
MorphoSys’s emphasis on its clinical-stage cancer programs puts the spotlight on a myelofibrosis drug candidate from its 2021 acquisition of Constellation Pharmaceuticals. That small molecule could compete against drug candidates from GSK and Merck.
January 9, 2023
EQS-News: MorphoSys AG / Key word(s): ConferenceMorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024 09.01.2023 / 07:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, January 9, 2023 Morp...
January 5, 2023
EQS-News: MorphoSys AG / Key word(s): ForecastMorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability 05.01.2023 / 11:38 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Release  Planegg/Munich, G...
January 5, 2023
Preliminary 2022 Monjuvi U.S. net product sales of US$ 89.4 million ( € 84.9 million)Anticipated 2023 Monjuvi U.S. net product sales in the range of US$ 80 to 95 millionPreliminary unaudited financial